[go: up one dir, main page]

MX9706588A - Metodo para estimular una respuesta inmune. - Google Patents

Metodo para estimular una respuesta inmune.

Info

Publication number
MX9706588A
MX9706588A MX9706588A MX9706588A MX9706588A MX 9706588 A MX9706588 A MX 9706588A MX 9706588 A MX9706588 A MX 9706588A MX 9706588 A MX9706588 A MX 9706588A MX 9706588 A MX9706588 A MX 9706588A
Authority
MX
Mexico
Prior art keywords
immune response
stimulating
individuals
pathogenic
ligand
Prior art date
Application number
MX9706588A
Other languages
English (en)
Inventor
Mark Alderson
Kim A Campbell
Mary K Kennedy
Charles R Maliszewski
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MX9706588A publication Critical patent/MX9706588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)

Abstract

Se describe un método para estimular una respuesta inmune que comprende administrar una cantidad efectiva de una proteína de union CD40. El método es util para tratar individuos infectados con organismos patogénicos u oportunistas e individuos que tienen una respuesta inmune deprimida. Las proteínas de union CD40 incluyen ligando CD40, anticuerpos monoclonales que se unen específicamente a CD40 y combinaciones de los mismos.
MX9706588A 1995-03-01 1996-02-29 Metodo para estimular una respuesta inmune. MX9706588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01
PCT/US1996/002839 WO1996026735A1 (en) 1995-03-01 1996-02-29 Method for stimulating an immune response

Publications (1)

Publication Number Publication Date
MX9706588A true MX9706588A (es) 1997-11-29

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706588A MX9706588A (es) 1995-03-01 1996-02-29 Metodo para estimular una respuesta inmune.

Country Status (15)

Country Link
EP (1) EP0812206B1 (es)
JP (1) JP3657271B2 (es)
KR (1) KR19980702490A (es)
AT (1) ATE220331T1 (es)
AU (1) AU699291B2 (es)
CA (1) CA2213798C (es)
DE (1) DE69622259T2 (es)
DK (1) DK0812206T3 (es)
ES (1) ES2179187T3 (es)
FI (1) FI973484A7 (es)
MX (1) MX9706588A (es)
NO (1) NO973875L (es)
NZ (1) NZ305083A (es)
PT (1) PT812206E (es)
WO (1) WO1996026735A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
EP1059932A1 (en) * 1997-12-19 2000-12-20 Immunex Corporation Method for reducing susceptibility to hiv infection
ES2330017T3 (es) * 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
MY188753A (en) 2006-09-18 2021-12-29 Univ Arkansas Compositions and methods of enhancing immune responses
JP2011502165A (ja) 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
EP2214701B1 (en) 2007-11-01 2016-08-03 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria
HUE037157T2 (hu) 2010-01-21 2018-08-28 Univ Arkansas Vakcinavektorok, és eljárások immunválaszok fokozására
PT2579901T (pt) 2010-06-09 2019-11-05 Univ Arkansas Vacina e métodos para reduzir infeção por campylobacter
US8778345B2 (en) 2011-04-29 2014-07-15 Apexigen, Inc. Anti-CD40 antibodies
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
MY173328A (en) 2013-02-14 2020-01-16 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
WO2014152508A1 (en) 2013-03-15 2014-09-25 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661360B2 (en) * 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
CA2172376C (en) * 1993-10-01 2008-11-18 William C. Fanslow, Iii Antibodies to cd40

Also Published As

Publication number Publication date
AU5301196A (en) 1996-09-18
ES2179187T3 (es) 2003-01-16
KR19980702490A (ko) 1998-07-15
WO1996026735A1 (en) 1996-09-06
CA2213798A1 (en) 1996-09-06
NZ305083A (en) 1999-06-29
FI973484L (fi) 1997-10-24
DE69622259T2 (de) 2003-03-27
DK0812206T3 (da) 2002-09-09
ATE220331T1 (de) 2002-07-15
NO973875L (no) 1997-10-31
JPH11506418A (ja) 1999-06-08
CA2213798C (en) 2001-02-06
NO973875D0 (no) 1997-08-22
FI973484A7 (fi) 1997-10-24
EP0812206B1 (en) 2002-07-10
AU699291B2 (en) 1998-11-26
FI973484A0 (fi) 1997-08-25
EP0812206A1 (en) 1997-12-17
DE69622259D1 (de) 2002-08-14
JP3657271B2 (ja) 2005-06-08
PT812206E (pt) 2002-11-29

Similar Documents

Publication Publication Date Title
MX9706588A (es) Metodo para estimular una respuesta inmune.
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
PT724456E (pt) Anticorpos contra cd4
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
DE69228701D1 (de) Fragmente von Prion Proteinen.
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
NO20001238L (no) Monoklonalt antistoff som induserer apoptose
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
EE9600192A (et) Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
ATE309371T1 (de) Protein mit dnase-aktivität
WO2022212654A3 (en) Cross-reactive monoclonal antibodies against coronaviruses
ATE478682T1 (de) Behandlung von krankheiten des nervensystems mit ziegenserum
ATE171545T1 (de) Verfahren zur bestimmung des lysingehaltes von samen
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees